Capricor Therapeutics Inc (CAPR) Stock Price

CAPRStock

$9.59+53.44%52W

Market Cap$557.55M

P/E—

PEG Ratio0.38

Div yield—

Beta0.50

CAPR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-77.52%

Price vs S&P 500 (4W)126.79%

PEG Ratio0.38

VGM Score45.14

Book Value / Share (Quarterly)$4.83

P/TBV (Annual)2.26x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)352.73%

Cash Flow / Share (Quarterly)$-1.98

Price vs S&P 500 (YTD)-79.39%

Net Profit Margin (TTM)-181.71%

EPS (TTM)$-2.31

10-Day Avg Trading Volume11.98M

EPS Excl Extra (TTM)$-2.31

Revenue Growth (5Y)85.64%

EPS (Annual)$-2.26

ROI (Annual)-33.64%

Net Profit Margin (5Y Avg)-2831.28%

Cash / Share (Quarterly)$4.83

ROA (Last FY)-29.51%

Revenue Growth TTM (YoY)-52.08%

EBITD / Share (TTM)$-2.39

ROE (5Y Avg)-94.15%

Operating Margin (TTM)-191.13%

Cash Flow / Share (Annual)$-1.42

P/B Ratio0.91x

P/B Ratio (Quarterly)6.27x

Net Income / Employee (Annual)$-454,700

EV / Revenue (TTM)6.89x

Net Interest Coverage (TTM)7.75x

ROA (TTM)-48.65%

EV / EBITDA (TTM)313.09x

EPS Incl Extra (Annual)$-2.26

Current Ratio (Annual)9.01x

Quick Ratio (Quarterly)8.28x

3-Month Avg Trading Volume4.45M

52-Week Price Return53.44%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$1.30

P/S Ratio (Annual)11.34x

Asset Turnover (Annual)0.13x

52-Week High$40.37

Operating Margin (5Y Avg)-2891.85%

EPS Excl Extra (Annual)$-2.26

CapEx CAGR (5Y)84.39%

Tangible BV CAGR (5Y)46.12%

26-Week Price Return-65.59%

Quick Ratio (Annual)8.88x

13-Week Price Return-67.09%

Total Debt / Equity (Annual)0.02x

Current Ratio (Quarterly)8.42x

Enterprise Value$153.41M

Revenue / Share Growth (5Y)18.36%

Asset Turnover (TTM)0.25x

Book Value / Share Growth (5Y)31.22%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-181.71%

Cash / Share (Annual)$5.55

3-Month Return Std Dev209.62%

Net Income / Employee (TTM)$-496,100

ROE (Last FY)-34.35%

Net Interest Coverage (Annual)-28.45x

EPS Basic Excl Extra (Annual)$-2.26

P/FCF (TTM)67.15x

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.02x

EPS Incl Extra (TTM)$-2.31

Receivables Turnover (Annual)0.00x

ROI (TTM)-57.81%

P/S Ratio (TTM)11.34x

Pretax Margin (5Y Avg)-2831.28%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$1.30

Forward P/E212.64x

Price vs S&P 500 (52W)34.88%

Year-to-Date Return-66.77%

5-Day Price Return41.03%

EPS Normalized (Annual)$-2.26

ROA (5Y Avg)-39.52%

Net Profit Margin (Annual)-181.71%

Month-to-Date Return149.09%

Cash Flow / Share (TTM)$-1.11

EBITD / Share (Annual)$-2.29

Operating Margin (Annual)-191.13%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-79.11%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.31

P/TBV (Quarterly)2.26x

P/B Ratio (Annual)5.13x

Pretax Margin (TTM)-181.71%

Book Value / Share (Annual)$5.33

Price vs S&P 500 (13W)-69.04%

Beta0.50x

P/FCF (Annual)161.86x

Revenue / Share (TTM)$0.00

ROE (TTM)-59.27%

52-Week Low$2.96

vGradeD

gGradeC

mGradeC

vgmGradeC

CAPR Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 13, 2026	-$0.58	-$0.70	-21.62%(-$0.12)
Q4 2025	Mar 12, 2026	-$0.55	-$0.62	-12.43%(-$0.07)
Q3 2025	Nov 10, 2025	-$0.54	-$0.54	+0.26%(+$0.00)
Q2 2025	Aug 11, 2025	-$0.48	-$0.57	-19.37%(-$0.09)

CAPR Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.13

4.19

2.67

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
CAPRCapricor Therapeutics Inc	D	C	C	$9.59
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Capricor Therapeutics Inc

Capricor Therapeutics is a clinical-stage biotechnology company developing cell and exosome-based therapies for rare diseases with high unmet medical needs. Its lead candidate, deramiocel (an allogeneic cardiac-derived cell therapy), is in Phase 3 clinical development for Duchenne muscular dystrophy. The company's proprietary StealthX platform supports preclinical research in vaccine delivery and targeted molecular therapeutics.